Positive U.S. Launch of Genio
Following FDA approval, Nyxoah's Genio device received strong enthusiasm in the U.S., generating USD 231,000 in revenue during Q3 and completing 15 implants across 9 accounts by the end of October.
Surgeon and Payer Adoption
111 surgeons were trained, 102 value analysis committee submissions completed, and reimbursement secured with Medicare and 10 private payers including UnitedHealthcare, Blue Cross Blue Shield, and Cigna.
Significant Revenue Growth
Reported revenue of EUR 2 million in Q3 2025, a 56% increase from EUR 1.3 million in Q3 2024.
Strategic Financial Positioning
Nyxoah secured up to $77 million in funding, including a $25 million private equity placement and a $52 million convertible bond, ensuring capital runway into Q1 2027.